Lupin 2024

AAM opposes latest prescription drug reform framework

Print Friendly, PDF & Email

WASHINGTON — In response to press reports on the current framework on prescription drug policies, AAM and its Biosimilars Council issued the following statement on the potential impact to patient access to generic and biosimilar medicines:

“Patient access to more affordable generic and biosimilar medicines would be threatened under the policies currently under consideration in Congress. Competition from lower-cost generics and biosimilars has successfully led to decades of savings for patients. Continued access and savings to more affordable medicines would be jeopardized should these policies advance.

AAM strongly opposes an approach to direct negotiations in Medicare that would undermine biosimilar and generic development. Combined with inflation-based rebates on generics and biosimilars, the reforms being considered would upend the competitive framework envisioned with Hatch-Waxman and BPCIA and threaten sustainable patient access to more affordable medicine.

We strongly encourage Congress to advance policies that enhance generic and biosimilar competition and lead to meaningful savings at the pharmacy counter for patients.”


ECRM_06-01-22


Comments are closed.

Centrum 7/6  banner